Short Interest in Traws Pharma, Inc. (NASDAQ:TRAW) Rises By 1,956.5%

Traws Pharma, Inc. (NASDAQ:TRAW) saw a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 141,900 shares, a growth of 1,956.5% from the December 15th total of 6,900 shares. Based on an average daily volume of 503,100 shares, the days-to-cover ratio is currently 0.3 days. Currently, 5.2% of the shares of the company are sold short.

Traws Pharma Price Performance

NASDAQ TRAW traded down $0.73 on Monday, hitting $7.33. 490,459 shares of the stock traded hands, compared to its average volume of 250,405. The stock’s fifty day simple moving average is $6.41. Traws Pharma has a 12 month low of $4.06 and a 12 month high of $27.50. The company has a market cap of $22.18 million, a price-to-earnings ratio of -0.05 and a beta of 1.13.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.